Wedbush Reaffirms “Outperform” Rating for Miragen Therapeutics (MGEN)

Wedbush reiterated their outperform rating on shares of Miragen Therapeutics (NASDAQ:MGEN) in a research report report published on Tuesday. Wedbush also issued estimates for Miragen Therapeutics’ FY2022 earnings at ($0.96) EPS.

MGEN has been the topic of several other reports. Zacks Investment Research downgraded shares of Miragen Therapeutics from a buy rating to a hold rating in a research note on Thursday, January 25th. Cann initiated coverage on shares of Miragen Therapeutics in a research note on Friday, January 12th. They issued an outperform rating and a $13.00 target price on the stock. Evercore ISI initiated coverage on shares of Miragen Therapeutics in a research note on Friday, March 9th. They issued an outperform rating and a $19.00 target price on the stock. Oppenheimer initiated coverage on shares of Miragen Therapeutics in a research note on Friday, January 12th. They issued an outperform rating and a $13.00 target price on the stock. Finally, Chardan Capital reaffirmed a buy rating on shares of Miragen Therapeutics in a research note on Tuesday, January 16th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company’s stock. Miragen Therapeutics has an average rating of Buy and a consensus target price of $16.59.

How to Become a New Pot Stock Millionaire

Shares of Miragen Therapeutics (NASDAQ MGEN) opened at $7.61 on Tuesday. The firm has a market cap of $229.01, a P/E ratio of -5.07 and a beta of 1.64. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.33 and a quick ratio of 13.33. Miragen Therapeutics has a one year low of $5.01 and a one year high of $15.91.

Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, March 14th. The medical research company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.22 million. Miragen Therapeutics had a negative net margin of 662.30% and a negative return on equity of 63.57%. equities analysts anticipate that Miragen Therapeutics will post -1.25 EPS for the current fiscal year.

In related news, Director Bruce Booth purchased 545,454 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were acquired at an average price of $5.50 per share, for a total transaction of $2,999,997.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Adam Scott Levy purchased 9,090 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was bought at an average price of $5.50 per share, for a total transaction of $49,995.00. Following the acquisition, the insider now owns 10,540 shares of the company’s stock, valued at $57,970. The disclosure for this purchase can be found here. 44.40% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC boosted its holdings in Miragen Therapeutics by 372.8% in the fourth quarter. Virtu Financial LLC now owns 51,896 shares of the medical research company’s stock valued at $541,000 after acquiring an additional 40,920 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Miragen Therapeutics during the 3rd quarter valued at $250,000. Aveo Capital Partners LLC bought a new stake in shares of Miragen Therapeutics during the 4th quarter valued at $279,000. Russell Investments Group Ltd. bought a new stake in shares of Miragen Therapeutics during the 3rd quarter valued at $147,000. Finally, Deutsche Bank AG boosted its holdings in shares of Miragen Therapeutics by 437.4% during the 4th quarter. Deutsche Bank AG now owns 60,917 shares of the medical research company’s stock valued at $634,000 after buying an additional 49,581 shares in the last quarter. Institutional investors and hedge funds own 19.83% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Wedbush Reaffirms “Outperform” Rating for Miragen Therapeutics (MGEN)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3290602/wedbush-reaffirms-outperform-rating-for-miragen-therapeutics-mgen.html.

Miragen Therapeutics Company Profile

Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.

Analyst Recommendations for Miragen Therapeutics (NASDAQ:MGEN)

Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MKS Instruments  Releases Q2 Earnings Guidance
MKS Instruments Releases Q2 Earnings Guidance
Vipshop  versus Qurate Retail Group  Critical Contrast
Vipshop versus Qurate Retail Group Critical Contrast
Reviewing Chunghwa Telecom  and Cellcom
Reviewing Chunghwa Telecom and Cellcom
Gnosis  Market Capitalization Hits $123.05 Million
Gnosis Market Capitalization Hits $123.05 Million
VoteCoin Price Up 215% This Week
VoteCoin Price Up 215% This Week
Dashcoin  Tops One Day Volume of $1,507.00
Dashcoin Tops One Day Volume of $1,507.00


© 2006-2018 Ticker Report. Google+.